Comparison of the curative effect and safety of consolidation chemotherapy after concurrent chemoradiotherapy with concurrent chemoradiotherapy alone for locally advanced cervical cancer

Purpose: This study investigated the curative effect and safety of consolidation chemotherapy in locally advanced cervical cancer. Materials and Methods: Eighty-four patients with locally advanced cervical cancer, treated in the Department of Gynaecological Oncology at JiangXi Maternal and Child Health Hospital of China between January 2011 and January 2013, were retrospectively enrolled. Forty-six patients underwent three courses of platinum-based consolidation chemotherapy following concurrent chemoradiotherapy (consolidation group), and 38 patients underwent concurrent chemoradiotherapy only (control group). Effectiveness, feasibility, survival rates, and toxicity were evaluated. Results: Follow-up was 15 to 54 months. Treatment strategy (HR=0.322, 95% CI: 0.123-0.843, p = 0.021) and cancer stage (HR=2.333, 95% CI: 1.043-5.218, p = 0.039) were associated with overall survival rate. Severe myelosuppression in the consolidation group was 36.96% and 18.42% in the control group, (p = 0.19), serious adverse events of the rectum were 10.87%, and 13.16%, respectively (p = 0.749). Conclusion: Consolidation chemotherapy increased patient survival but not the incidence of severe adverse events.

Locally advanced cervical cancer; Consolidation chemotherapy; Survival rate.

[1] Siegel R., Naishadham D., Jemal A.: “Cancer statistics, 2013”. CA Cancer J. Clin., 2013, 63, 11.

[2] Galic V., Herzog T.J., Lewin S.N., Neugut A.I., Burke W.M., Lu Y.S., et al.: “Prognostic significance of adenocarcinoma histology in women with cervical cancer”. Gynecol. Oncol., 2012, 125, 287.

[3] Shimada M., Nishimura R., Nogawa T., Hatae M., Takehara K., Yamada H., et al.: “Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjuvant radiotherapy following radical surgery: SGSG/TGCU Intergroup Surveillance”. Mol. Clin. Oncol., 2013, 1, 780.

[4] Petric Mise B., Boraska Jelavic T., Strikic A., Hrepic D., Tomic K., Hamm W., et al.: “Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy”. Int. J. Gynecol. Cancer, 2015, 25, 315.

[5] Keys H.M., Bundy B.N., Stehman F.B., Muderspach L.I., Chafe W.E., Suggs C.L., 3rd, et al.: “Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma”. N. Engl. J. Med., 1999, 340, 1154.

[6] Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenback C., Stevens R.E., et al.: “Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer”. N. Engl. J. Med., 1999, 340, 1137.

[7] Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., et al.: “Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer”. N. Engl. J.

Med., 1999, 340, 1144.

[8] Whitney C.W., Sause W., Bundy B.N., Malfetano J.H., Hannigan E.V., Fowler W.C., Jr., et al.: “Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative paraaortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study”. J. Clin. Oncol., 1999, 17, 1339.

[9] Peters W.A., 3rd, Liu P.Y., Barrett R.J., 2nd, Stock R.J., Monk B.J., Berek J.S., et al.: “Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix”. J. Clin. Oncol., 2000, 18, 1606.

[10] Rose P.G.: “Chemoradiotherapy for cervical cancer”. Eur. J. Cancer, 2002, 38, 270.

[11] Chemoradiotherapy for Cervical Cancer Meta-Analysis C.: “Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials”. J. Clin. Oncol., 2008, 26, 5802.

[12] Choi C.H., Lee Y.Y., Kim M.K., Kim T.J., Lee J.W., Nam H.R., et al.: “A matched-case comparison to explore the role of consolidation chemotherapy after concurrent chemoradiation in cervical cancer”. Int. J. Radiat. Oncol. Biol. Phys., 2011, 81, 1252.

[13] Duenas-Gonzalez A., Zarba J.J., Patel F., Alcedo J.C., Beslija S., Casanova L., et al.: “Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix”. J. Clin. Oncol., 2011, 29, 1678.

[14] Zhang M.Q., Liu S.P., Wang X.E.: “Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study”. Int. J. Radiat. Oncol. Biol. Phys., 2010, 78, 821.

[15] “Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0 (CTCA)”. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf

[16] Kim H.S., Kim M.K., Kim H.J., Han S.S., Kim J.W.: “Phase II study of consolidation chemotherapy after adjuvant or primary concurrent chemoradiation using paclitaxel and carboplatin to treat high-risk early-stage or locally advanced cervical cancer”. Cancer Res. Treat., 2012, 44, 97.

[17] Zhao E.F., Bao L., Li C., Song L., Li Y.L.: “Changes in epidemiology and clinical characteristics of cervical cancer over the past 50 years”. Di Yi Jun Yi Da Xue Xue Bao, 2005, 25, 605.

[18] Castellsague X., Diaz M., de Sanjose S., Munoz N., Herrero R., Franceschi S., et al.: “Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention”. J. Natl. Cancer Inst., 2006, 98, 303.